How pharmaceutical companies break through the terminal of the pharmaceutical investment market

A clear orientation - When the pharmaceutical development in China has entered a new era in which channels have been digging deep and specialized marketing and promotion as the core, the entire industry environment is rapidly following this direction. This requires that enterprises must follow this trend in the development of the industry to change, according to their own existing product resources and market customer resources, positioning the company's main channels or markets, and then follow the actual situation in the channel of professional operation. Only in this way can we ensure that pharmaceutical investment enterprises can establish themselves in the future market competition. Some of the investment enterprises have already begun this attempt from a few years ago and have achieved good results.

The strategy of "policy marketing" - the management of enterprises, is carried out under the direction of industry development and government guidance. Pharmaceutical investment promotion companies are no exception. When the unscrupulous business that my own business pharmaceutical investment companies are used to, attracting profits by attracting individuals to collect points and deducting profits through the use of a margin to gain benefits, only gradually realize that a reasonable interpretation of market development and policy guidance. , is the core of the company's future operations. The policy-centric marketing trend is gradually becoming apparent, and this trend will gradually subside in the coming period of quite a while with the advancement of China's health care reform.

In the coming years, the restructuring of the pharmaceutical industry under the leadership of the government will be more detailed. At this time, “following the policy, we will be able to eat meat.” How to grasp policies, adapt policies, interpret policies, and marketing policies will be a big issue for all pharmaceutical investment companies in the future.

The in-depth excavation of product value--Now, these non-medical insurance, agricultural insurance, and essential medicines owned by pharmaceutical investment merchants do not have to be restricted by hard targets such as national price limits, and current levels of medical institutions and sales channels occupy a considerable amount. The proportion of these varieties is still a key to participating in market competition. What the pharmaceutical investment enterprises need to do is not to gradually eliminate these varieties from the enterprise's product management system, but to re-investigate and tap the potential value of these products through specialized means, and treat each variety as a newly listed clinical drug. Research, use professional means to maintain the market sales life cycle of these products, and as a supplemental source of interest after the company occupies the market through basic drugs, etc., as far as possible to make these varieties bigger and stronger.

Protecting the market interest chain - The business model of pharmaceutical investment enterprises determines that the core issue of market protection is the core problem that all pharmaceutical investment enterprises cannot solve and have to face. It is often a product that is easy to advertise, advertise, and recruit. As a result, due to the lack of market grasp, lack of attention to market protection, or blind pursuit of the number of customers and sales volume, the phenomenon of market rush-out of goods has become apparent. In a very short period of time, the market that has been successfully recruited has rapidly declined, and investment promotion companies and agents have not received any results. Some benefits. Therefore, it is imperative for pharmaceutical investment promotion companies to develop and promote the market protection work without delay.